Patents Assigned to Medical Research Council
  • Publication number: 20190062812
    Abstract: The invention relates to a method for the diagnosis of TB in a subject, the method comprising (a) providing a sample from said subject, said sample being selected from the group consisting of: blood, serum and plasma; (b) determining the concentration in said sample of the following biomarkers: IL-1ra, IL6, IL-7, IL-8, IL-12p70, FGF-basic, IP-10, and VEGF; (c) converting each biomarker concentration determined in (b) into a decile value; and (d) converting each decile value into a binary presence or absence by comparing the decile values of (c) to the following specific quantile cut off values wherein a decile value matching or exceeding the specific quantile cut-off value is converted into the binary presence of the biomarker, and a decile value lower than the specific quantile cut-off value is converted into the binary absence of the biomarker; wherein detecting the presence of each of said biomarkers indicates that the subject has TB. The invention also relates to uses, kits and devices.
    Type: Application
    Filed: February 3, 2017
    Publication date: February 28, 2019
    Applicants: Medical Research Council, Imperial Innovations Limited
    Inventors: Beate KAMPMANN, Toyin TOGUN, Clive HOGGART
  • Publication number: 20190024261
    Abstract: The invention describes a method for the synthesis of compounds comprising the steps of: (a) compartmentalizing two or more sets of primary compounds into microcapsules; such that a proportion of the microcapsules contains two or more compounds; and (b) forming secondary compounds in the microcapsules by chemical reaction between primary compounds from different sets; wherein one or both of steps (a) and (b) is performed under microfluidic control; preferably electronic microfluidic control. The invention further allows for the identification of compounds which bind to a target component of a biochemical system or modulate the activity of the target, and which is co-compartmentalized into the microcapsules.
    Type: Application
    Filed: December 8, 2017
    Publication date: January 24, 2019
    Applicants: President and Fellows of Harvard College, Medical Research Council
    Inventors: Andrew David Griffiths, David A. Weitz, Darren Roy Link, Keunho Ahn, Jerome Bibette
  • Publication number: 20180282395
    Abstract: The present invention relates to mutant transmembrane proteins which have increased conformational stability when compared to their parent protein, methods of selection and production. In particular the invention relates to mutant transmembrane proteins which are mutated in or in the proximity of the transmembrane alpha helices or in a kinked region or in an alpha-helix adjacent to a kink. The mutant transmembrane proteins have use in crystallisation studies and also in screening to identify compounds for use in drug discovery and therapy.
    Type: Application
    Filed: February 12, 2018
    Publication date: October 4, 2018
    Applicant: Medical Research Council
    Inventor: Christopher Gordon Tate
  • Publication number: 20180272299
    Abstract: The invention describes a method for the synthesis of compounds comprising the steps of: (a) compartmentalising two or more sets of primary compounds into microcapsules; such that a proportion of the microcapsules contains two or more compounds; and (b) forming secondary compounds in the microcapsules by chemical reactions between primary compounds from different sets; wherein one or both of steps (a) and (b) is performed under microfluidic control; preferably electronic microfluidic control The invention further allows for the identification of compounds which bind to a target component of a biochemical system or modulate the activity of the target, and which is co-compartmentalised into the microcapsules.
    Type: Application
    Filed: March 15, 2018
    Publication date: September 27, 2018
    Applicants: President and Fellows of Harvard College, Medical Research Council
    Inventors: Andrew David Griffiths, David A. Weitz, Darren Roy Link, Keunho Ahn, Jerome Bibette
  • Publication number: 20180271784
    Abstract: Processes for recovering colloids of carboxylate ligand modified ferric iron hydroxide materials such as IHAT (Iron Hydroxide Adipate Tartrate) are described based on the use of water miscible non-aqueous solvents, such as ethanol, methanol and acetone. The processes produce materials with advantageous properties such as improved bioavailability, reduced aggregation and/or agglomeration and/or increased iron content.
    Type: Application
    Filed: October 7, 2016
    Publication date: September 27, 2018
    Applicant: Medical Research Council
    Inventors: Jonathan Joseph POWELL, Nuno Jorge Rodrigues FARIA
  • Publication number: 20180237756
    Abstract: The invention relates to a nucleic acid polymerase capable of producing a non-DNA nucleotide polymer from a DNA nucleotide template, said polymerase comprising amino acid sequence having at least 36% identity to the amino acid sequence of SEQ ID NO:1, wherein said amino acid sequence is mutated relative to the amino acid sequence of SEQ ID NO:1 at one or more residues of the thumb region, said residues selected from: amino acids 651 to 679 (patch 10A); wherein said amino acid sequence is mutated relative to the amino acid sequence of SEQ ID NO:1 at residue E664. In one embodiment said polymerase comprises the mutations Y409G and E664K. In one embodiment said polymerase comprises amino acid sequence corresponding to SEQ ID NO:12.
    Type: Application
    Filed: March 13, 2018
    Publication date: August 23, 2018
    Applicant: MEDICAL RESEARCH COUNCIL
    Inventors: Philipp Holliger, Christopher Cozens, Vitor B. Pinheiro, Alexander I. Taylor
  • Patent number: 10052605
    Abstract: Methods for use in the synthesis and identification of molecules which bind to a target component of a biological system or modulate the activity of a target are described.
    Type: Grant
    Filed: April 29, 2010
    Date of Patent: August 21, 2018
    Assignee: Medical Research Council
    Inventors: Andrew David Griffiths, Chris Abell, Florian Hollfelder, Enrico Mastrobattista
  • Publication number: 20180147177
    Abstract: Antibacterial compositions comprising nanoparticles formed from copper oxo-hydroxide are described that are capable of delivering biocidal concentrations of copper, typically in the form of free copper ions (Cu2+). The nanoparticle compositions generally comprise small particles, typically having mean diameters in the range of 1-100 nm, having comparatively high surface area-to-volume ratio and enhanced reactivity compared to the corresponding bulk counterpart materials and which are sufficiently labile to release the free copper efficiently.
    Type: Application
    Filed: April 22, 2016
    Publication date: May 31, 2018
    Applicant: Medical Research Council
    Inventors: Carlos André Passos BASTOS, Sylvaine Francoise Aline BRUGGRABER, Nuno Jorge Rodrigues FARIA, Jonathan Joseph POWELL
  • Patent number: 9968690
    Abstract: The invention relates to a polypeptide comprising an amino acid having a norbornene group. Suitably said norbornene group is present as an amino acid residue of a norbornene lysine. The invention also relates to a method of producing a polypeptide comprising a norbornene group, said method comprising genetically incorporating an amino acid comprising a norbornene group into a polypeptide.
    Type: Grant
    Filed: January 21, 2013
    Date of Patent: May 15, 2018
    Assignees: Medical Research Council, North Carolina State University
    Inventors: Jason Chin, Alexander Deiters, Kathrin Lang
  • Publication number: 20180125801
    Abstract: The present invention discloses a method to discover selective inhibitors of phosphatases.
    Type: Application
    Filed: April 8, 2016
    Publication date: May 10, 2018
    Applicant: MEDICAL RESEARCH COUNCIL
    Inventors: Anne BERTOLOTTI, Indrajit DAS, Agnieszka KRZYZOSIAK, Adrien ROUSSEAU, Kim SCHNEIDER, Anna Gudny SIGURDARDOTTIR
  • Patent number: 9963474
    Abstract: The invention relates to compounds having Formula (1): A-L-B or pharmaceutically acceptable salts thereof, wherein: A is a dicarbonyl sequestering moiety comprising a substituted aryl group or a substituted heteroaryl group; L is an optional linker moiety; and B is a mitochondrial targeting moiety. The invention also relates to pharmaceutical compositions containing such compounds and salts, and to the use of such compounds and salts for treating diabetes, preferably hyperglycemic diabetes. A mass spectrometry probe and to a method of labelling a biological molecule 1 for mass spectrometry detection are also described.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: May 8, 2018
    Assignee: Medical Research Council
    Inventors: Michael Patrick Murphy, Robin Andrew James Smith, Richard Charles Hartley
  • Publication number: 20180111896
    Abstract: The present invention relates to inhibitors of PPP1 R15A and PPP1 R15B and their use in therapy, particularly in the treatment of a disease state alleviated by the inhibition of PPP1 R15A and PPP1 R15B, for example a disorder associated with accumulation of misfolded proteins or proteostatsis disorder. Compounds of the invention include compounds having the formula IA or a pharmaceutically acceptable salt thereof, wherein R1a, R3a, R5a, Xa and Ya are as defined herein.
    Type: Application
    Filed: April 8, 2016
    Publication date: April 26, 2018
    Applicant: MEDICAL RESEARCH COUNCIL
    Inventors: Anne BERTOLOTTI, Indrajit DAS, Agnieszka KRZYZOSIAK, Adrien ROUSSEAU, Kim SCHNEDIDER, Anna Gudny SICURDARDOTTIR
  • Patent number: 9947505
    Abstract: Some embodiments are directed to a support for receiving a biological sample, the support comprising at least one support member, and including graphene attached to the support member. The graphene is partially hydrogenated graphene. Some embodiments are also directed to use of a partially hydrogenated graphene surface to support a biological molecule for electron microscopy. Some other embodiments are also directed to a method for making a partially hydrogenated graphene. The method includes applying a hydrogen ion or hydrogen atom to the surface of graphene. The hydrogen ion or hydrogen atom is applied at an energy in the range 1 to 21 eV. A sensor comprising a surface capable of adsorbing a biological molecule thereto is also disclosed, wherein said surface includes partially hydrogenated graphene.
    Type: Grant
    Filed: August 7, 2014
    Date of Patent: April 17, 2018
    Assignee: MEDICAL RESEARCH COUNCIL
    Inventors: Christopher J. Russo, Lori A. Passmore
  • Patent number: 9938511
    Abstract: The invention relates to a nucleic acid polymerase capable of producing a non-DNA nucleotide polymer from a DNA nucleotide template, said polymerase comprising amino acid sequence having at least 36% identity to the amino acid sequence of SEQ ID NO:1, wherein said amino acid sequence is mutated relative to the amino acid sequence of SEQ ID NO:1 at one or more residues of the thumb region, said residues selected from: amino acids 651 to 679 (patch 10A); wherein said amino acid sequence is mutated relative to the amino acid sequence of SEQ ID NO:1 at residue E664. In one embodiment said polymerase comprises the mutations Y409G and E664K. In one embodiment said polymerase comprises amino acid sequence corresponding to SEQ ID NO:12.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: April 10, 2018
    Assignee: Medical Research Council
    Inventors: Philipp Holliger, Christopher Cozens, Vitor B. Pinheiro, Alexander I. Taylor
  • Patent number: 9932385
    Abstract: The present invention relates to mutant transmembrane proteins which have increased conformational stability when compared to their parent protein, methods of selection and production. In particular the invention relates to mutant transmembrane proteins which are mutated in or in the proximity of the transmembrane alpha helices or in a kinked region or in an alpha-helix adjacent to a kink. The mutant transmembrane proteins have use in crystallization studies and also in screening to identify compounds for use in drug discovery and therapy.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: April 3, 2018
    Assignee: Medical Research Council
    Inventor: Christopher Gordon Tate
  • Patent number: 9925504
    Abstract: The invention describes a method for the synthesis of compounds comprising the steps of: (a) compartmentalizing two or more sets of primary compounds into microcapsules; such that a proportion of the microcapsules contains two or more compounds; and (b) forming secondary compounds in the microcapsules by chemical reactions between primary compounds from different sets; wherein one or both of steps (a) and (b) is performed under microfluidic control; preferably electronic microfluidic control The invention further allows for the identification of compounds which bind to a target component of a biochemical system or modulate the activity of the target, and which is co-compartmentalized into the microcapsules.
    Type: Grant
    Filed: December 20, 2006
    Date of Patent: March 27, 2018
    Assignees: President and Fellows of Harvard College, Medical Research Council
    Inventors: Andrew Griffiths, David Weitz, Keunho Ahn, Darren Link, Jerome Bibette
  • Patent number: 9925501
    Abstract: The invention describes a method for isolating one or more genetic elements encoding a gene product having a desired activity, comprising the steps of: (a) compartmentalising genetic elements into microcapsules; and (b) sorting the genetic elements which express the gene product having the desired activity; wherein at least one step is under microfluidic control. The invention enables the in vitro evolution of nucleic acids and proteins by repeated mutagenesis and iterative applications of the method of the invention.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: March 27, 2018
    Assignees: Medical Research Council, President and Fellows of Harvard College
    Inventors: Andrew David Griffiths, David A. Weitz, Darren R. Link, Keunho Ahn, Jerome Bibette
  • Patent number: 9919277
    Abstract: The invention describes a method for isolating one or more genetic elements encoding a gene product having a desired activity, comprising the steps of: (a) compartmentalising genetic elements into microcapsules; and (b) sorting the genetic elements which express the gene product having the desired activity; wherein at least one step is under microfluidic control. The invention enables the in vitro evolution of nucleic acids and proteins by repeated mutagenesis and iterative applications of the method of the invention.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: March 20, 2018
    Assignees: Medical Research Council, President and Fellows of Harvard College
    Inventors: Andrew David Griffiths, David A. Weitz, Darren Roy Link, Keunho Ahn, Jerome Bibette
  • Patent number: 9914914
    Abstract: The invention relates to a nucleic acid polymerase capable of producing a non-DNA nucleotide polymer from a DNA nucleotide polymer template, the polymerase comprising amino acid sequence having at least 36% identity to the amino acid sequence of SEQ ID NO: 1, wherein the amino acid sequence is mutated relative to the amino acid sequence of SEQ ID NO: 1, wherein the amino acid sequence comprises the mutations P657T, E658Q, K659H, Y663H, D669A, K671N, and T676I; wherein the amino acid sequence is further mutated relative to the amino acid sequence of SEQ ID NO: 1 at residue: E664 and wherein the amino acid sequence comprises the mutation E664K. The invention also relates to methods of making nucleotide polymers comprising use of this polymerase. Suitably the nucleotides are arabino nucleotides such as ARA or FANA nucleotides.
    Type: Grant
    Filed: April 19, 2013
    Date of Patent: March 13, 2018
    Assignee: Medical Research Council
    Inventors: Philipp Holliger, Chris Cozens, Vitor Pinheiro
  • Publication number: 20180044729
    Abstract: A method for determining the sequence of nucleotide bases in a polynucleotide analyte is provided. It is characterised by the steps of (1) generating a stream of single nucleotide bases from the analyte by pyrophosphorolysis; (2) producing captured molecules by reacting each single nucleotide base with a capture system labelled with detectable elements in an undetectable state; (3) releasing the detectable elements from each captured molecule in a detectable state and (4) detecting the detectable elements so released and determining the sequence of nucleotide bases therefrom. The method can be used advantageously in sequencers involving the use of microdroplets.
    Type: Application
    Filed: October 5, 2017
    Publication date: February 15, 2018
    Applicants: BASE4 INNOVATION LTD, MEDICAL RESEARCH COUNCIL
    Inventors: Cameron Alexander FRAYLING, Barnaby BALMFORTH, Bruno Flavio Nogueira de Sousa SOARES, Thomas Henry ISAAC, Boris BREINER, Alessandra NATALE, Michele AMASIO, Paul DEAR